These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33428130)

  • 41. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.
    Hansen HH; Barkholt P; Fabricius K; Jelsing J; Terwel D; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Mar; 1634():158-170. PubMed ID: 26746341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective Disruption of Inhibitory Synapses Leading to Neuronal Hyperexcitability at an Early Stage of Tau Pathogenesis in a Mouse Model.
    Shimojo M; Takuwa H; Takado Y; Tokunaga M; Tsukamoto S; Minatohara K; Ono M; Seki C; Maeda J; Urushihata T; Minamihisamatsu T; Aoki I; Kawamura K; Zhang MR; Suhara T; Sahara N; Higuchi M
    J Neurosci; 2020 Apr; 40(17):3491-3501. PubMed ID: 32265258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy.
    Buccarello L; Grignaschi G; Castaldo AM; Di Giancamillo A; Domeneghini C; Melcangi RC; Borsello T
    J Alzheimers Dis; 2017; 56(4):1279-1292. PubMed ID: 28157099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.
    McKenzie-Nickson S; Chan J; Perez K; Hung LW; Cheng L; Sedjahtera A; Gunawan L; Adlard PA; Hayne DJ; McInnes LE; Donnelly PS; Finkelstein DI; Hill AF; Barnham KJ
    ACS Chem Neurosci; 2018 Nov; 9(11):2731-2740. PubMed ID: 29920069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.
    Ma QL; Zuo X; Yang F; Ubeda OJ; Gant DJ; Alaverdyan M; Teng E; Hu S; Chen PP; Maiti P; Teter B; Cole GM; Frautschy SA
    J Biol Chem; 2013 Feb; 288(6):4056-65. PubMed ID: 23264626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of cornel iridoid glycoside on microglia activation through suppression of the JAK/STAT signalling pathway.
    Qu Z; Zheng N; Wei Y; Chen Y; Zhang Y; Zhang M; Chang H; Liu J; Ai H; Geng X; Wang Q; Yin L
    J Neuroimmunol; 2019 May; 330():96-107. PubMed ID: 30852182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice.
    Gamache J; Benzow K; Forster C; Kemper L; Hlynialuk C; Furrow E; Ashe KH; Koob MD
    Nat Commun; 2019 Jun; 10(1):2479. PubMed ID: 31171783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo axonal transport deficits in a mouse model of fronto-temporal dementia.
    Majid T; Ali YO; Venkitaramani DV; Jang MK; Lu HC; Pautler RG
    Neuroimage Clin; 2014; 4():711-7. PubMed ID: 24936422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synaptic alterations in the rTg4510 mouse model of tauopathy.
    Kopeikina KJ; Polydoro M; Tai HC; Yaeger E; Carlson GA; Pitstick R; Hyman BT; Spires-Jones TL
    J Comp Neurol; 2013 Apr; 521(6):1334-53. PubMed ID: 23047530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age-dependent impairment of memory and neurofibrillary tangle formation and clearance in a mouse model of tauopathy.
    Kubota T; Kirino Y
    Brain Res; 2021 Aug; 1765():147496. PubMed ID: 33894222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cornel Iridoid glycoside attenuated brain edema of the cerebral ischemia/reperfusion rats by modulating the polarized aquaporin 4.
    Wang Z; Xue F; Zhang J; Wang Y; Hu E; Zheng Y; Luo X; Li H; Qiao B
    Fitoterapia; 2024 Sep; 177():106098. PubMed ID: 38950636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model.
    Fox LM; William CM; Adamowicz DH; Pitstick R; Carlson GA; Spires-Jones TL; Hyman BT
    J Neuropathol Exp Neurol; 2011 Jul; 70(7):588-95. PubMed ID: 21666499
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
    Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
    Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperphosphorylated Tau Relates to Improved Cognitive Performance and Reduced Hippocampal Excitability in the Young rTg4510 Mouse Model of Tauopathy.
    Xolalpa-Cueva L; García-Carlos CA; Villaseñor-Zepeda R; Orta-Salazar E; Díaz-Cintra S; Peña-Ortega F; Perry G; Mondragón-Rodríguez S
    J Alzheimers Dis; 2022; 87(2):529-543. PubMed ID: 35342085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. S-Adenosylmethionine Rescues Cognitive Deficits in the rTg4510 Animal Model by Stabilizing Protein Phosphatase 2A and Reducing Phosphorylated Tau.
    Beauchamp LC; Liu XM; Sedjahtera A; Bogeski M; Vella LJ; Bush AI; Adlard PA; Barnham KJ
    J Alzheimers Dis; 2020; 77(4):1705-1715. PubMed ID: 32925070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TAPPing into the potential of inducible tau/APP transgenic mice.
    Xu G; Ulm BS; Howard J; Fromholt SE; Lu Q; Lee BB; Walker A; Borchelt DR; Lewis J
    Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12791. PubMed ID: 35067965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.
    DeVos SL; Corjuc BT; Commins C; Dujardin S; Bannon RN; Corjuc D; Moore BD; Bennett RE; Jorfi M; Gonzales JA; Dooley PM; Roe AD; Pitstick R; Irimia D; Frosch MP; Carlson GA; Hyman BT
    Brain; 2018 Jul; 141(7):2194-2212. PubMed ID: 29733334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endogenous tau aggregates in oligodendrocytes of rTg4510 mice induced by human P301L tau.
    Ren Y; Lin WL; Sanchez L; Ceballos C; Polydoro M; Spires-Jones TL; Hyman BT; Dickson DW; Sahara N
    J Alzheimers Dis; 2014; 38(3):589-600. PubMed ID: 24028867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei.
    Dutschmann M; Menuet C; Stettner GM; Gestreau C; Borghgraef P; Devijver H; Gielis L; Hilaire G; Van Leuven F
    J Neurosci; 2010 Feb; 30(5):1810-21. PubMed ID: 20130190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.